IRLAB THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.85 SEK | -0.72% |
|
-9.77% | +84.67% |
| May. 27 | Sweden’s IRLAB Therapeutics Names New CEO | MT |
| May. 27 | IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,578 | 2,173 | 2,277 | 1,987 | 389 | 718.4 | - |
| Enterprise Value (EV) 1 | 1,472 | 2,173 | 1,875 | 1,734 | 277.7 | 706.5 | 974.8 |
| P/E ratio | -15.4 x | -21.9 x | 44 x | -17.5 x | -2.19 x | -4.5 x | -3.87 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 60,685 x | - | 11 x | 32.5 x | 68.5 x | 10.9 x | 5.2 x |
| EV / Revenue | 56,609 x | - | 9.02 x | 28.4 x | 48.9 x | 10.8 x | 7.06 x |
| EV / EBITDA | -15.8 x | - | 33.5 x | -16 x | -1.57 x | -4.62 x | -5.61 x |
| EV / FCF | -16,114,113 x | - | - | - | -1,681,496 x | - | - |
| FCF Yield | -0% | - | - | - | -0% | - | - |
| Price to Book | - | - | - | 6.83 x | - | - | - |
| Nbr of stocks (in thousands) | 43,110 | 51,748 | 51,748 | 51,868 | 51,868 | 51,868 | - |
| Reference price 2 | 36.60 | 42.00 | 44.00 | 38.30 | 7.500 | 13.85 | 13.85 |
| Announcement Date | 2/6/20 | 4/15/21 | 2/23/22 | 2/23/23 | 2/7/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.026 | - | 207.8 | 61.14 | 5.678 | 65.65 | 138.1 |
| EBITDA 1 | -92.92 | - | 56.05 | -108.3 | -176.4 | -152.9 | -173.6 |
| EBIT 1 | -95.85 | - | 52.58 | -113.1 | -180.8 | -110.1 | -21.78 |
| Operating Margin | -368,646.15% | - | 25.3% | -185.01% | -3,183.6% | -167.68% | -15.77% |
| Earnings before Tax (EBT) 1 | -96.12 | - | 51.78 | -113.4 | -177.8 | -160 | -185.5 |
| Net income 1 | -96.12 | -91.65 | 51.78 | -113.4 | -177.8 | -111.3 | -27.13 |
| Net margin | -369,692.31% | - | 24.92% | -185.5% | -3,132.07% | -169.49% | -19.64% |
| EPS 2 | -2.370 | -1.920 | 1.000 | -2.190 | -3.430 | -3.080 | -3.580 |
| Free Cash Flow | -91.34 | - | - | - | -165.2 | - | - |
| FCF margin | -351,300% | - | - | - | -2,908.65% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 4/15/21 | 2/23/22 | 2/23/23 | 2/7/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|
| Net sales 1 | 9.042 | 23.41 | 16.5 |
| EBITDA 1 | -28.14 | -26.06 | -22.91 |
| EBIT 1 | -29.09 | -27.02 | -23.92 |
| Operating Margin | -321.7% | -115.4% | -144.97% |
| Earnings before Tax (EBT) 1 | -29.17 | -27.12 | -23.96 |
| Net income 1 | -29.17 | -27.12 | -23.96 |
| Net margin | -322.61% | -115.83% | -145.17% |
| EPS 2 | -0.5600 | -0.5200 | -0.4600 |
| Dividend per Share | - | - | - |
| Announcement Date | 5/11/22 | 8/24/22 | 11/9/22 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 256 |
| Net Cash position 1 | 106 | - | 402 | 253 | 111 | 11.9 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -1.477 x |
| Free Cash Flow | -91.3 | - | - | - | -165 | - | - |
| ROE (net income / shareholders' equity) | -48.8% | - | - | -32.9% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | 5.610 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 0.71 | 2.88 | 0.29 | 0.3 | 0.3 |
| Capex / Sales | - | - | 0.34% | 4.7% | 5.16% | 0.46% | 0.22% |
| Announcement Date | 2/6/20 | 4/15/21 | 2/23/22 | 2/23/23 | 2/7/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +84.67% | 68.88M | |
| +48.53% | 779B | |
| +40.67% | 631B | |
| -6.37% | 354B | |
| +20.93% | 333B | |
| +8.21% | 301B | |
| +16.75% | 249B | |
| -1.19% | 216B | |
| +10.85% | 214B | |
| +4.40% | 163B |
- Stock Market
- Equities
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
